Skip to content

Clinical trials

Observational Hypercapnia trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hypercapnia Phase: Observational Clear all

31 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20112
20121
20134
20142
20153
20164
20181
20191
20212
20221
20242
20252
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed16
Recruiting5
Unknown status5
Terminated3
Not yet recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institutes of Health Clinical Center (CC)2
University of Lausanne Hospitals2
Air Liquide Healthcare Spain1
Assistance Publique - Hôpitaux de Paris1
Association pour la Recherche en Physiologie de l'Environnement1
Cantonal Hosptal, Baselland1
Catholic University of the Sacred Heart1
Centre Hospitalier Sud Francilien1
Centre Hospitalier Universitaire de Besancon1
European Society of Intensive Care Medicine1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hypercapnia31
Hypoxia9
Respiratory Insufficiency8
Pulmonary Disease, Chronic Obstructive4
Dyspnea2
Hyperoxia2
Obesity Hypoventilation Syndrome2
Postoperative Complications2
Acid-Base Imbalance1
Acidosis1

Trials

Showing 76 to 31 of 31. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.